Juan Manuel Manuel Schammas

Mr. Juan Manuel Manuel Schammas


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Virology
Verified
Journal Article
Closed access
DBDanilo Bucafusco
Danilo Bucafusco
SGSebastián Di Giacomo
Sebastián Di Giacomo
JPJuan Pega
Juan Pega
JSJuan Manuel Manuel Schammas
Juan Manuel Manuel Schammas
NCNancy Patricia Cardoso
Nancy Patricia Cardoso
Daniel Mariano Pérez-FilgueiraDaniel Mariano Pérez-Filgueira
Daniel Mariano Pérez-Filgueira

15 August 2022 in Viruses
Verified
Journal Article
Open access
PDF file
SGSebastián Di Giacomo
Sebastián Di Giacomo
DBDanilo Bucafusco
Danilo Bucafusco
JSJuan Manuel Manuel Schammas
Juan Manuel Manuel Schammas
JPJuan Pega
Juan Pega
MMMaría Cruz Cruz Miraglia
María Cruz Cruz Miraglia
Daniel Mariano Pérez-FilgueiraDaniel Mariano Pérez-Filgueira
Daniel Mariano Pérez-Filgueira
Foot-and-mouth disease (FMD) remains one of the major threats to animal health worldwide. Its causative agent, the FMD virus (FMDV), affects cloven-hoofed animals, including farm animals and wildlife species, inflicting severe damage to the international trade and livestock industry. FMDV antigenic variability remains one of the biggest challenges for vaccine-based control strategies. The current study analyzed the host’s adaptive immune responses in cattle immunized with different vaccine protocols and investigated its associations with the clinical outcome after infection with a heterologous strain of FMDV. The results showed that antigenic payload, multivalency, and revaccination may impact on the clinical outcome after heterologous challenge with FMDV. Protection from the experimental infection was related to qualitative traits of the elicited antibodies, such as avidity, IgG isotype composition, and specificity diversity, modulating and reflecting the vaccine-induced maturation of the humoral response. The correlation analyses of the serum avidity obtained per vaccinated individual might suggest that conventional vaccination can induce high-affinity immunoglobulins against conserved epitopes even within different FMDV serotypes. Cross-reaction among strains by these high-affinity antibodies may support further protection against a heterologous infection with FMDV.

10 October 2024 in Viruses
Verified
Journal Article
Open access
PDF file
MVMaría Aldana Vissani
María Aldana Vissani
FAFlorencia Alamos
Florencia Alamos
MTMaria Silvia Tordoya
Maria Silvia Tordoya
LMLeonardo Minatel
Leonardo Minatel
JSJuan Manuel Manuel Schammas
Juan Manuel Manuel Schammas
MCMariano Carossino
Mariano Carossino
Western equine encephalitis virus (WEEV) is a mosquito-borne arbovirus (genus Alphavirus, family Togaviridae) that has re-emerged in South America in late 2023, causing severe disease in both horses and humans after a nearly 40-year intermission period. We here describe the virological, serological, pathological, and molecular features of WEEV infection in horses during the 2023–2024 outbreak in Argentina. WEEV-infected horses developed neurological signs with mild to severe encephalitis associated with minimal to abundant WEEV-infected cells, as demonstrated by WEEV-specific in situ hybridization. The distribution of viral RNA was multifocal, with predominance within neuronal bodies, neuronal processes, and glial cells in the medulla oblongata and thalamic regions. Phylogenetic analysis of partial nsP4 sequences from three viral isolates obtained from three different provinces of Argentina support grouping with other temporally current WEEV strains from Uruguay and Brazil under a recently proposed novel lineage.

25 January 2024 in Viruses
Verified
Journal Article
Open access
PDF file
FPFlorencia Pavan
Florencia Pavan
MBMarina Bok
Marina Bok
RJRafael Betanzos San Juan
Rafael Betanzos San Juan
JMJuan Pablo Malito
Juan Pablo Malito
GMGISELA MARCOPPIDO
GISELA MARCOPPIDO
LILorena Itatí Ibañez
Lorena Itatí Ibañez
Since the beginning of the COVID-19 pandemic, there has been a significant need to develop antivirals and vaccines to combat the disease. In this work, we developed llama-derived nanobodies (Nbs) directed against the receptor binding domain (RBD) and other domains of the Spike (S) protein of SARS-CoV-2. Most of the Nbs with neutralizing properties were directed to RBD and were able to block S-2P/ACE2 interaction. Three neutralizing Nbs recognized the N-terminal domain (NTD) of the S-2P protein. Intranasal administration of Nbs induced protection ranging from 40% to 80% after challenge with the WA1/2020 strain in k18-hACE2 transgenic mice. Interestingly, protection was associated with a significant reduction in virus replication in nasal turbinates and a reduction in virus load in the brain. Employing pseudovirus neutralization assays, we identified Nbs with neutralizing capacity against the Alpha, Beta, Delta, and Omicron variants, including a Nb capable of neutralizing all variants tested. Furthermore, cocktails of different Nbs performed better than individual Nbs at neutralizing two Omicron variants (B.1.529 and BA.2). Altogether, the data suggest the potential of SARS-CoV-2 specific Nbs for intranasal treatment of COVID-19 encephalitis.